Hexadecanoic acid 3-nitro-2-oxo-2H-chromen-8-yl ester

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: Hexadecanoic acid 3-nitro-2-oxo-2H-chromen-8-yl ester
• 英文别名: (3-Nitro-2-oxochromen-8-yl) hexadecanoate
• 化学式: C₂₅H₃₅NO₆
• 分子量: 445.556
• InChiKey: BAXZAVXQFQFLEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  32
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  98.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,3-二羟基苯甲醛 在 N-甲基吗啉 、 2,6-二甲基吡啶 、 4-二甲氨基吡啶 、 四氯化钛 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 Hexadecanoic acid 3-nitro-2-oxo-2H-chromen-8-yl ester
  参考文献：
  名称：

  Phospholipase C Inhibitors: A New Class of Agents

  摘要：

  A series of nitrocoumarin and nitrochromene derivatives have been prepared and shown to inhibit the phosphatidylinositol-specific phospholipase C(PLC)(IC50 < 10 mu g/mL) isolated from human melanoma. The inhibition of PLC by nitrocoumarin 4a was time-dependent and irreversible. The inhibition of PLC was shown to interfere with inositide metabolism in whole cells (IC50 = 4 mu g/mL) in a manner consistent with their proposed mode of activity, Finally, the compounds were shown to be growth inhibitory to cultured melanoma cells (ID50 = 2 mu g/ML), suggesting that PLC may be an attractive new target for chemotherapeutic intervention.

  DOI：

  10.1021/jm00040a016

文献信息

• Perrella Frank W., Chen Shih-Fong, Behrens Davette L., Kaltenbach Robert +, J. Med. Chem, 37 (1994) N 14, S 2232-2237
  作者：Perrella Frank W., Chen Shih-Fong, Behrens Davette L., Kaltenbach Robert +

  DOI：——

  日期：——
• Phospholipase C Inhibitors: A New Class of Agents
  作者：Frank W. Perrella、Shih-Fong Chen、Davette L. Behrens、Robert F. III Kaltenbach、Steven P. Seitz

  DOI：10.1021/jm00040a016

  日期：1994.7

  A series of nitrocoumarin and nitrochromene derivatives have been prepared and shown to inhibit the phosphatidylinositol-specific phospholipase C(PLC)(IC50 < 10 mu g/mL) isolated from human melanoma. The inhibition of PLC by nitrocoumarin 4a was time-dependent and irreversible. The inhibition of PLC was shown to interfere with inositide metabolism in whole cells (IC50 = 4 mu g/mL) in a manner consistent with their proposed mode of activity, Finally, the compounds were shown to be growth inhibitory to cultured melanoma cells (ID50 = 2 mu g/ML), suggesting that PLC may be an attractive new target for chemotherapeutic intervention.